 MONT-SAINT-GUIBERT, Belgium--BUSINESS WIRE--Regulatory News: Celyad Oncology SA Euronext Nasdaq: CYAD Brussels:CYAD Paris:CYAD NASDAQ:CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company will report first half 2022 financial and operating results on the morning of Friday, August 5, 2022. Following the press release, Celyad Oncology management will h 